Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2823-2830

  Anderson, Helen L ^a   Yap, Jeffrey T ^a   Miller, Mathew P ^a   Robbins, Adele ^a   Jones, Terry ^a   Price, Patricia M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; COMBRETASTATIN A4 PHOSPHATE; OXYGEN 15; ANTINEOPLASTIC AGENT; COMBRETASTATIN A 4; COMBRETASTATIN A-4; STILBENE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; HUMAN; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID TUMOR; SPLEEN BLOOD FLOW; TISSUE PERFUSION; TUMOR BLOOD FLOW; ADULT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; IMAGE PROCESSING; INFUSION PUMP; KIDNEY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NONPARAMETRIC TEST; SCINTISCANNING; SPLEEN; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSION PUMPS; KIDNEY; MALE; MIDDLE AGED; NEOPLASMS; SPLEEN; STATISTICS, NONPARAMETRIC; STILBENES; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0042887593     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.186     Document Type: Article

References (37)

1. Folkman J: Angiogenesis research: From laboratory to clinic. Forum Genova 9:59-62, 1999
2. Liekens S, De Clercq E, Neyts J: Angiogenesis: Regulators and clinical applications. Biochem Pharmacol 61:253-270, 2001
3. Chaplin DJ, Dougherty GJ: Tumour vasculature as a target for cancer therapy. Br J Cancer 80:57-64, 1999 (suppl 1)
4. Chaplin DJ, Hill SA, Bell KM, et al: Modification of tumor blood flow: Current status and future directions. Semin Radiat Oncol 8:151-163, 1998
5. Nihei Y, Suzuki M, Okano A, et al: Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90:1387-1395, 1999
6. Pettit GR, Singh SB, Niven ML, et al: Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50:119-131, 1987
7. Lin CM, Singh SB, Chu PS, et al: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Mol Pharmacol 34:200-208, 1988
8. Lin CM, Ho HH, Pettit GR, et al: Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28:6984-6991, 1989
9. Dark GG, Hill SA, Prise VE, et al: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834, 1997
10. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195, 1999
11. Tozer GM, Prise VE, Wilson J, et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 59:1626-1634, 1999
12. Galbraith SM, Chaplin DJ, Lee F, et al: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:93-102, 2001
13. Tozer GM, Prise VE, Wilson J, et al: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 61:6413-6422, 2001
14. Beauregard DA, Hill SA, Chaplin DJ, et al: The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61:6811-6815, 2001
15. Herbst RS, Lee AT, Tran HT, et al: Clinical studies of angiogenesis inhibitors: The University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 3:131-140, 2001
16. Braybrooke JP, O'Byrne KJ, Propper DJ, et al: A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 6:4697-4704, 2000
17. O'Donnell AE, Trigo JM, Banerji U, et al: A phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast MRI assessment of vascular permeability. Proc Am Assoc Cancer Res 19, 2000 (abstr 685)
18. Anderson H, Price P: Clinical measurement of blood flow in tumours using PET: A review. Nucl Med Commun 23 131-138, 2002
19. Taniguchi H, Koyama H, Masuyama M, et al: Angiotensin-II-induced hypertension chemotherapy: Evaluation of hepatic blood flow with oxygen-15 PET. J Nucl Med 37:1522-1523, 1996
20. 15O-water for monitoring prostate cancer during a phase II anti-angiogenic trial with thalidomide. Clin Positron Imaging 3:144, 2000
21. Mullani NA, Herbst RS, Abbruzzese JL, et al: Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. Clin Positron Imaging 3:151, 2000
22. Rustin GJS, Galbraith SM, Anderson H, et at: Phase I clinical trial of weekly combretastatin A4 Phosphate (CA4P): Clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822, 2003
23. Ranicar AS, Williams CW, Schnorr L, et al: The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. Med Prog Technol 17:259-264, 1991
24. Kety SS: Theory of blood tissue exchange and its application to measurement of blood now. Methods Med Res 8:223-227, 1960
25. Lammertsma AA, Cunningham VJ, Deiber MP, et al: Combination of dynamic and integral methods for generating reproducible functional CBF images. J Cereb Blood Flow Metab 10:675-686, 1990
26. Yap JT, Rhodes CG, Cunningham VJ, et al: Measurement of cardiac output during PET tumor blood flow studies. J Nucl Med 41:182, 2000
27. Zhao S, Moore JV, Waller ML, et al: Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med 26:231-238, 1999
28. Murata R, Overgaard J, Horsman MR: Comparative effects of combretastatin A-4 disodium phosphate and 5, 6-dimethylxamhenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 77:195-204, 2001
29. Malcontenti-Wilson C, Muralidharan V, Skinner S, et al: Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7:1052-1060, 2001
30. Horsman MR, Murata R, Breidahl T, et al: Combretastatin's novel vascular targeting drugs for improving anti-cancer therapy: Combretastatins and conventional therapy. Adv Exp Med Biol 476:311-323, 2000
31. Murata R, Siemann DW, Overgaard J, et at: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60:155-161, 2001
32. Parkins CS, Holder AL, Hill SA, et al: Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide. Br J Cancer 83:811-816, 2000
33. Wilson CB, Lammertsma AA, McKenzie CG, et al: Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 52:1592-1597, 1992
34. Grosios K, Loadman PM, Swaine DJ, et al: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20:229-233, 2000
35. Nelkin BD, Ball DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8:157-160, 2001
36. Landuyt W, Ahmed B, Nuyts S, et al: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49:443-450, 2001
37. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-903, 1998